Ozempic vs Mounjaro
Brand name comparison of two leading GLP-1 medications for type 2 diabetes management.
Last updated: January 28, 2026
Semaglutide
Tirzepatide
Overview
Ozempic and Mounjaro are brand names for two of the most widely prescribed GLP-1-based medications for type 2 diabetes. Ozempic contains semaglutide (a GLP-1 receptor agonist), while Mounjaro contains tirzepatide (a dual GLP-1/GIP receptor agonist).
Both are FDA-approved for type 2 diabetes, administered via weekly subcutaneous injection, and have demonstrated significant efficacy in clinical trials.
Key Facts
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| Generic Name | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approval | 2017 (T2D) | 2022 (T2D) |
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist |
Mechanism Comparison
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP |
| Action | Single agonist | Dual agonist |
| Insulin Release | Enhanced | Enhanced (two pathways) |
| Glucagon Suppression | Yes | Yes |
How They Work
Ozempic (Semaglutide):
- Activates GLP-1 receptors
- Increases glucose-dependent insulin secretion
- Slows gastric emptying
- Reduces appetite via central mechanisms
Mounjaro (Tirzepatide):
- Activates both GLP-1 and GIP receptors
- May provide synergistic metabolic effects
- Enhanced insulin response through dual signaling
- Potentially greater beta-cell benefits
Clinical Trial Evidence
Efficacy for Type 2 Diabetes
| Trial Program | Ozempic (SUSTAIN) | Mounjaro (SURPASS) |
|---|---|---|
| A1C Reduction | 1.0-1.8% | 1.8-2.4% |
| Weight Loss | 4-6 kg | 5-12 kg |
| Participants | 8,000+ across program | 7,000+ across program |
Head-to-Head Data
The SURPASS-2 trial compared tirzepatide to semaglutide 1mg:
- Tirzepatide showed greater A1C reductions at all dose levels
- Tirzepatide showed greater weight loss
- Both had similar GI side effect profiles
Safety Comparison
Common Side Effects
| Side Effect | Ozempic | Mounjaro |
|---|---|---|
| Nausea | Common | Common |
| Diarrhea | Common | Common |
| Vomiting | Common | Common |
| Constipation | Less common | Common |
| Injection site reactions | Rare | Rare |
Warnings
Both medications carry similar warnings:
- Thyroid C-cell tumors: Boxed warning (rodent studies)
- Pancreatitis: Risk consideration
- Diabetic retinopathy: Monitor in patients with history
- Hypoglycemia: When used with insulin/sulfonylureas
- Acute kidney injury: Dehydration risk with GI effects
Key Differences
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Mechanism | Single receptor | Dual receptor |
| Time on Market | Longer (2017) | Newer (2022) |
| Trial Data Volume | More long-term data | Less long-term data |
| Cardiovascular Data | SELECT trial completed | CV outcomes trial ongoing |
Regulatory Status
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| T2D Approval | FDA approved (2017) | FDA approved (2022) |
| Weight Loss | Wegovy (separate brand) | Zepbound (separate brand) |
| Cardiovascular | CV risk reduction claim | Pending |
Summary
Both Ozempic and Mounjaro are effective, FDA-approved medications for type 2 diabetes:
- Ozempic: Established GLP-1 agonist with extensive real-world data and cardiovascular outcomes evidence
- Mounjaro: Newer dual agonist with potentially greater efficacy for glycemic control and weight loss in trials
The choice between them involves clinical considerations including:
- Individual response to therapy
- Specific metabolic goals
- Insurance coverage and access
- Cardiovascular risk profile
This comparison is for educational purposes only. Medication decisions should be made with a healthcare provider.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.